News
FDA approves Fitbit’s AFib-detection software
- Author:
- Catherine Hackett
Fitbit has gained approval for an algorithm that will power an upcoming AFib-detection feature.
News
POISE-3 backs wider use of tranexamic acid in noncardiac surgery
- Author:
- Patrice Wendling
- Catherine Hackett
The antifibrinolytic agent significantly reduced the risk for bleeding in a wide array of major noncardiac surgeries, suggesting an expanded role...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Viona_metf_621_recall_web.jpg)
FDA: More metformin extended-release tablets recalled
- Author:
- Catherine Hackett
Two lots of 750-mg metformin HCl tablets were recalled by Viona after testing revealed nitrosodimethylamine (...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/FDA_icon3_web.jpg)
FDA approves metoclopramide nasal spray for diabetic gastroparesis
- Author:
- Catherine Hackett
Via nasal administration, Gimoti bypasses the GI tract and enters the bloodstream directly for more “predictable...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Chicago_Day_web.jpg)
ACC is canceled. Now what?
- Author:
- Catherine Hackett
Safety concerns and travel restrictions drove the college’s decision to cancel ACC.20/WCC, but parts of the...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/FDA_approved_web.jpg)
Icosapent ethyl approved for cardiovascular risk reduction
- Author:
- Catherine Hackett
The Food and Drug Administration’s decision on reduction of events in high-risk patients was based primarily on the REDUCE-IT trial results.
News
Hyperkalemia-related treatment changes linked to death in acute HF
- Author:
- Catherine Hackett
It’s not the potassium, but the subsequent dosage reduction, that may boost mortality after hospitalization for acute heart failure.
Video
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Image/November-2018/capture_13.jpg)
‘Phenomenal’ REDUCE-IT establishes triglyceride theory
- Author:
- Catherine Hackett
Why did REDUCE-IT succeed while other trials and compounds failed? Dr. Deedwania explains that it, for the first time, used the appropriate...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/fda_icon2_web.jpg)
Rivaroxaban gains indication for prevention of major cardiovascular events in CAD/PAD
- Author:
- Catherine Hackett
Rivaroxaban (Xarelto) is the first direct oral anticoagulant to gain an indication for prevention of cardiovascular events.
Audio
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Image/October-2018/cardiocast_mdedge-300x300.png)
Metabolic swings predict death, hold the antiplatelet, and more
- Author:
- Catherine Hackett
Listen to the week’s top news on Cardiocast.
Audio
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Image/September-2018/cardiocast.png)
Top news from TCT, anticoagulation guidelines, and more
- Author:
- Catherine Hackett
Listen to the week’s news on Cardiocast.
News
Dapagliflozin meets endpoint in top-line DECLARE results, AstraZeneca says
- Author:
- Catherine Hackett
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/fda_icon2_web.jpg)
Eluvia drug-eluting vascular stent approved on heels of TCT presentation
- Author:
- Catherine Hackett
The stent system made a splash at TCT 2018.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Image/September-2018/SanDiego_weather_web.jpg)
Connecting at TCT 2018
- Author:
- Catherine Hackett
The Transcatheter Cardiovascular Therapeutics meeting will host more than 10,000 attendees. Here’s how to stay...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Image/September-2018/SanDiegoConventionCenter_web.jpg)
TCT presents new, ‘massive’ integrated, hands-on learning center
- Author:
- Catherine Hackett
TCT is going back to its roots with a huge new training center.